Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $22.92 in the prior trading day, Avadel Pharmaceuticals plc (NASDAQ: AVDL) closed at $22.93, up 0.04%. In other words, the price has increased by $0.04 from its previous closing price. On the day, 0.72 million shares were traded. AVDL stock price reached its highest trading level at $23.0 during the session, while it also had its lowest trading level at $22.88.
Ratios:
Our goal is to gain a better understanding of AVDL by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 24.45 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 60.87. For the most recent quarter (mrq), Quick Ratio is recorded 2.37 and its Current Ratio is at 2.76. In the meantime, Its Debt-to-Equity ratio is 0.38 whereas as Long-Term Debt/Eq ratio is at 0.37.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 21 ’25 when Palczuk Linda bought 5,000 shares for $7.93 per share. The transaction valued at 39,640 led to the insider holds 67,900 shares of the business.
Thornton Peter J. bought 10,000 shares of AVDL for $80,450 on Jan 13 ’25. The Director now owns 104,055 shares after completing the transaction at $8.04 per share. On Jan 13 ’25, another insider, Ende Eric J, who serves as the Director of the company, bought 30,000 shares for $7.84 each. As a result, the insider paid 235,218 and bolstered with 208,900 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AVDL now has a Market Capitalization of 2246935552 and an Enterprise Value of 2185068288. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.01 while its Price-to-Book (P/B) ratio in mrq is 22.70. Its current Enterprise Value per Revenue stands at 8.792 whereas that against EBITDA is 809.584.
Stock Price History:
The Beta on a monthly basis for AVDL is 1.22, which has changed by 1.0519247 over the last 52 weeks, in comparison to a change of 0.1177547 over the same period for the S&P500. Over the past 52 weeks, AVDL has reached a high of $23.57, while it has fallen to a 52-week low of $6.38. The 50-Day Moving Average of the stock is 29.60%, while the 200-Day Moving Average is calculated to be 92.19%.
Shares Statistics:
The stock has traded on average 2.73M shares per day over the past 3-months and 3192230 shares per day over the last 10 days, according to various share statistics. A total of 97.23M shares are outstanding, with a floating share count of 93.28M. Insiders hold about 4.48% of the company’s shares, while institutions hold 85.83% stake in the company. Shares short for AVDL as of 1763078400 were 6654943 with a Short Ratio of 2.82, compared to 1760486400 on 9982108. Therefore, it implies a Short% of Shares Outstanding of 6654943 and a Short% of Float of 7.95.
Earnings Estimates
. The current market rating for Avadel Pharmaceuticals plc (AVDL) reflects the collective analysis of 6.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.12, with high estimates of $0.17 and low estimates of $0.08.
Analysts are recommending an EPS of between $0.79 and $0.11 for the fiscal current year, implying an average EPS of $0.3. EPS for the following year is $0.78, with 7.0 analysts recommending between $1.14 and $0.58.
Revenue Estimates
5 analysts predict $80.3M in revenue for . The current quarter. It ranges from a high estimate of $83M to a low estimate of $79.3M. As of . The current estimate, Avadel Pharmaceuticals plc’s year-ago sales were $50.41MFor the next quarter, 5 analysts are estimating revenue of $80.07M. There is a high estimate of $87M for the next quarter, whereas the lowest estimate is $75M.
A total of 5 analysts have provided revenue estimates for AVDL’s current fiscal year. The highest revenue estimate was $281.1M, while the lowest revenue estimate was $274.9M, resulting in an average revenue estimate of $277.73M. In the same quarter a year ago, actual revenue was $169.12MBased on 10 analysts’ estimates, the company’s revenue will be $359.06M in the next fiscal year. The high estimate is $378.3M and the low estimate is $345.1M.
